World Pharma News

Home News Channels Contact Us Search XING Forums Members Login

Conferences & Events Cellular Imaging & Analysis 2008 Event by European Pharmaceutical Review Sales Force Effectiveness Russia-CIS Strategic Marketing and Branding for the Pharmaceutical Industry Workshop on molecular targets for cancer, Bergen, Norway	Research & Development First call for Innovative Medicines Initiative a success GlaxoSmithKline teams up with academia to develop new medicines of value New FP7 eHealth Project - preDiCT BASF and Transinsight agree to collaborate in exploring alternatives to animal testing
Read more...	Read more...

Welcome

World Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.

Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free service delivered by FeedBurner).

Non progredi est regredi.

World Pharma News .net

Explore the first worldwide Web 2.0 pharmaceutical news portal and 'Vote', 'Comment' or 'Submit' pharmaceutical news articles or other pharmaceutical web resources!
For further information, please visit http://www.worldpharmanews.net

Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.

Email:

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

Pharmaceutical RSS News

Start your day with worldwide pharmaceutical

news
[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]

European Commission

European Commission - Pharmaceuticals
FDA

FDA

US Food and Drug Administration

Sponsored Ads

Sponsored Ads

World Pharma News .net / Published News

Our RSS News Channels

ATOM 0.3

OPML

Sponsored Ads

GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.

GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration to enable the discovery of new medicines
Industry and academia link up in pioneering agreement
GSK sets out new strategic priorities
In a presentation to investors today, Andrew Witty, CEO GlaxoSmithKline, set out three new strategic priorities that aim to increase growth, reduce risk and improve GSK?s long-term financial performance.
Results announcement for the second quarter 2008
Results announced for the second quarter 2008 on Wednesday 23 July
GSK enters transformational agreement with Aspen to drive growth in emerging markets
GlaxoSmithKline (GSK) today announced a transformational agreement to significantly extend its pharmaceutical portfolio in emerging markets.
Dan Troy appointed as Senior Vice President and General Counsel for GlaxoSmithKline
Dan Troy has been appointed as Senior Vice President and General Counsel for GlaxoSmithKline (GSK), and will join the company on 2nd September 2008.
GlaxoSmithKline teams up with academia to develop new medicines of value
University of Cambridge to pioneer drug development by ?academic incubators?.
GlaxoSmithKline reaches settlement agreement with Biota
GlaxoSmithKline plc (GSK) today announced that it has reached a settlement in the litigation with Biota Holdings Limited regarding the commercialisation of Relenza (zanamivir).
GlaxoSmithKline and Actelion enter into exclusive collaboration to realise the full potential of almorexant in sleep disorders and beyond
GlaxoSmithKline and Actelion to potentially co-develop and co-commercialise other orexin receptor antagonists.
GSK receives BITC CommunityMark for global community programmes
GlaxoSmithKline (GSK) today became one of the first companies to be awarded the new CommunityMark by the UK organisation Business in the Community (BITC).
GSK and Aspen enter product divestment agreement
GlaxoSmithKline (GSK) today announced that it has agreed to sell four products, Eltroxin, Lanoxin, Imuran and Zyloric to a subsidiary of the South African based pharmaceuticals group, Aspen Global Incorporated for a cash consideration of �170 million.

Submit to World Pharma News .net

Sponsored Ads

↑ Grab this Headline Animator

Product Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows GlaxoSmithKline responds to FDA on Cervarix� and plans to submit final study data for approval Cervarix�, GSK's cervical cancer vaccine, wins tender for UK national immunisation programme Genzyme Files Applications for Approval of Mozobil in the United States and Europe Romiplostim Data Show Potential Long-Term Efficacy and Safety	Clinical Trials Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128 Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies International study to evaluate efficacy and safety in treating a leading cause of blindness	Corporate Boehringer Ingelheim FENS Award for exceptional research in neuroscience Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case Summary Judgment Granted for SEROQUEL Patent Litigation in the US Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development Abbott and Partnership for a Drug-Free America Launch 'Not In My House'	Financial Pfizer Reports Second-Quarter 2008 Results Novartis gains momentum with strong performance in first half of 2008 Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter Novartis completes acquisition of 25% stake in Alcon from Nestl� Shire proposes acquisition of Jerini AG for an equity purchase price of �328 million
Read more...	Read more...	Read more...	Read more...

© World Pharma News - All rights reserved. Terms and Conditions | Contact Us